Lantheus Agrees to $8 Billion Curium Merger Amid Mixed Q2 Results — Lantheus Holdings, Inc.

Event summary

Lantheus reported a 2.7% revenue increase to $388.2 million in Q2 2026, with GAAP EPS down slightly from $1.12 to $1.11.
PYLARIFY sales declined 4.1%, while DEFINITY sales rose 5.2%.
Curium agreed to acquire Lantheus for up to $8 billion, including a $102.50 per share cash offer and potential CVRs worth up to $12 per share.
Lantheus suspended its full-year 2026 guidance due to the pending merger.

The big picture

The merger with Curium positions the combined entity as a leading radiopharmaceutical player, spanning diagnostics and therapeutics. However, Lantheus's mixed Q2 results highlight challenges in sustaining growth amid competitive pressures. The $8 billion deal reflects broader consolidation trends in the healthcare sector as companies seek scale to drive innovation and cost efficiencies.

What we're watching

Integration Challenges: The pace at which Lantheus and Curium can integrate operations will determine whether the combined entity achieves expected synergies.
Regulatory Approvals: How quickly regulators approve the merger could impact the timeline for realizing strategic benefits.
Product Performance: Whether Lantheus can stabilize or reverse declining sales of PYLARIFY will be critical to maintaining shareholder confidence.